Show simple item record

dc.contributor.authorSalomon-Escoto, Karen I.
dc.contributor.authorGravallese, Ellen M.
dc.contributor.authorKay, Jonathan
dc.date2022-08-11T08:10:51.000
dc.date.accessioned2022-08-23T17:22:30Z
dc.date.available2022-08-23T17:22:30Z
dc.date.issued2011-08-01
dc.date.submitted2015-02-25
dc.identifier.citationBest Pract Res Clin Rheumatol. 2011 Aug;25(4):497-507. doi: 10.1016/j.berh.2011.10.007. <a href="http://dx.doi.org/10.1016/j.berh.2011.10.007">Link to article on publisher's site</a>
dc.identifier.issn1521-6942 (Linking)
dc.identifier.doi10.1016/j.berh.2011.10.007
dc.identifier.pmid22137920
dc.identifier.urihttp://hdl.handle.net/20.500.14038/48759
dc.description.abstractAs very effective targeted biological therapies have become available to treat rheumatoid arthritis (RA), remission is now the goal of treatment. Since 1981, efforts have been undertaken to develop criteria for clinical remission in RA. Although several different measures of disease activity have been proposed, many issues remain unresolved. Active joint inflammation, even if involving only a few joints, negatively impacts a patient's quality of life and may ultimately result in structural damage. Thus, a low disease activity state (LDAS), which has been adopted as the target in clinical trials of 'treat to target', may not be the optimal treatment target in clinical practice. Similarly, the definitions of remission used in clinical trials may not be appropriate for use in daily clinical practice because some allow for the presence of several tender and swollen joints. Measures of disease activity do not necessarily correlate with structural remission, which implies halting progression of radiographic evidence of damage over time. Because no single measure of RA disease activity fully quantifies the global burden of disease, rheumatologists must follow multiple parameters to assess disease activity thoroughly and to adjust treatment optimally.
dc.language.isoen_US
dc.relation<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=22137920&dopt=Abstract">Link to Article in PubMed</a>
dc.relation.urlhttp://dx.doi.org/10.1016/j.berh.2011.10.007
dc.subjectAntirheumatic Agents
dc.subjectArthritis, Rheumatoid
dc.subjectArthrography
dc.subjectClinical Trials as Topic
dc.subjectFemale
dc.subjectHealth Status
dc.subjectHumans
dc.subjectJoints
dc.subjectMale
dc.subjectOutcome Assessment (Health Care)
dc.subjectPain Measurement
dc.subjectPatient Satisfaction
dc.subjectQuality of Life
dc.subjectRecovery of Function
dc.subjectRemission Induction
dc.subjectTreatment Outcome
dc.subjectMusculoskeletal Diseases
dc.subjectRheumatology
dc.subjectSkin and Connective Tissue Diseases
dc.titleAssessment of control of rheumatoid arthritis disease activity
dc.typeJournal Article
dc.source.journaltitleBest practice and research. Clinical rheumatology
dc.source.volume25
dc.source.issue4
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/rheumatology_pubs/69
dc.identifier.contextkey6724725
html.description.abstract<p>As very effective targeted biological therapies have become available to treat rheumatoid arthritis (RA), remission is now the goal of treatment. Since 1981, efforts have been undertaken to develop criteria for clinical remission in RA. Although several different measures of disease activity have been proposed, many issues remain unresolved. Active joint inflammation, even if involving only a few joints, negatively impacts a patient's quality of life and may ultimately result in structural damage. Thus, a low disease activity state (LDAS), which has been adopted as the target in clinical trials of 'treat to target', may not be the optimal treatment target in clinical practice. Similarly, the definitions of remission used in clinical trials may not be appropriate for use in daily clinical practice because some allow for the presence of several tender and swollen joints. Measures of disease activity do not necessarily correlate with structural remission, which implies halting progression of radiographic evidence of damage over time. Because no single measure of RA disease activity fully quantifies the global burden of disease, rheumatologists must follow multiple parameters to assess disease activity thoroughly and to adjust treatment optimally.</p>
dc.identifier.submissionpathrheumatology_pubs/69
dc.contributor.departmentDepartment of Internal Medicine
dc.contributor.departmentDepartment of Medicine, Division of Rheumatology
dc.source.pages497-507


Files in this item

Thumbnail
Name:
Publisher version

This item appears in the following Collection(s)

Show simple item record